Interestingly, several studies have reported favorable therapeutic effects of ICI therapy in patients with cancer who have CTCs expressing PD-L1 in NSCLC [24,25], urothelial carcinoma [26], melanoma [27], and HCC [22]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.